Without a Ribbon
  • About
    • Events
    • Get In Touch
  • Rare Cancer Resources
  • Shop
  • How You Can Help
  • Meet Warriors
  • News
  • Login
  • Register

Select Page

HELP

LEARN

EVENTS

Pleomorphic Xanthoastrocytoma of the Brain

Become part of our growing rare cancer community.
Join our Facebook support group

Join Now

Posted by fatima.shakeel@opmc.co | Mar 7, 2025

What is Pleomorphic Xanthoastrocytoma (PXA) of the Brain?

Pleomorphic Xanthoastrocytoma of the Brain is a rare, typically slow-growing brain tumour that primarily affects children and young adults, with the average age at diagnosis being 12 years. It originates from astrocytes—cells in the brain that support nerve cells—and usually develops in the upper regions of the brain, known as the cerebral hemispheres. Although generally benign, PXAs can occasionally become more aggressive.​

Causes

The exact cause of PXA is not well understood. However, genetic mutations, particularly the BRAFV600E mutation, have been linked to the development of these tumours. In some cases, mutations in the TERT promoter gene have been associated with a lower survival rate.

Signs and Symptoms

Common symptoms of PXA include:

  • Seizures: Experienced by approximately 70% of individuals with PXA. ​
  • Headaches: Resulting from increased pressure within the brain due to the tumour.​
  • Hemiparesis: Weakness on one side of the body.​
  • Behavioral Changes: Such as confusion or mood alterations.​

Diagnosis

To diagnose PXA, doctors may use several methods:

  • Physical Examination: Assessing neurological function and symptoms.​
  • Imaging Tests: CT scans or MRIs to determine the tumour’s location, size, and extent.​
  • EEG (Electroencephalogram): Detecting abnormal brain activity, especially if seizures are present.​
  • Biopsy: Removing a small sample of the tumour tissue to confirm the diagnosis and determine the tumour type.​

Treatment

The primary treatment for PXA is surgical removal of the tumour. If the tumour recurs or cannot be completely removed, radiation therapy may be considered. In some instances, targeted therapies, such as BRAF inhibitors, have been used, especially in tumours with specific genetic mutations.

Treatment typically involves a multidisciplinary team, including neurosurgeons, neuro-oncologists, and radiation specialists, to provide comprehensive care. Molecular testing of the tumour can also guide treatment decisions and help identify the most effective therapy options.​


You can help us with your donation:

Without a Ribbon is a charity that works hard to aid those who suffer from rare cancers. You can help our cause in a variety of ways:

Donations — Without a Ribbon is grateful when we receive every donation. Giving to Without a Ribbon helps us to provide ongoing support, organise the annual gathering and subsidise the costs of our Warriors attending these conferences.
Sponsorship — If you wish to sponsor our charity, please contact us using this form.
Volunteering — We are always looking for volunteers to help with different aspects of running our charity. So, if you are looking for volunteer work, please feel free to contact us.

Share:

PreviousOur New Resource Page for Basal Cell Adenocarcinoma
NextOur New Resource Page for Pleomorphic Xanthoastrocytoma of the Brain

If you need any help or advice just

Get In Touch

© Without a Ribbon 2019. All rights reserved.Powered by WEB 105 Creative

Stay up to date.

Sign up to our newsletter